Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast Cancer

Tumor mutational burden (TMB), usually representing high immunogenicity, cannot always predict treatment response of immune checkpoint blockade (ICB). Here, it is showed that defective antigen cross‐presentation in type 1 conventional dendritic cells (cDC1) is responsible for lacking tumor‐specific cytotoxic T lymphocytes (CTLs) in triple‐negative breast cancer (TNBC) patients. Mechanistically, tumor cytosolic CDC37, shuttled via extracellular vesicles (EVs) into the endosomes of intratumor dendritic cells (DCs), inhibits antigen cross‐presentation by locking antigen binding to HSP90 and precluding their translocation from endosomes to cytoplasm. CDC37 knockdown in tumor cells or inhibiting CDC37/HSP90 interaction in DCs efficiently promotes antigen translocation and enhances their cross‐presentation, which improves ICB therapeutic responses. Clinically, high tumor CDC37 expression is associated with low infiltration of antigen‐specific CTLs and poor ICB efficacy in TNBC patients. Therefore, tumor EV‐shuttled CDC37 locks antigen/chaperone interaction and impairs antigen cross‐presentation in DCs. Moreover, targeting CDC37 is promising to enhance anti‐tumor immunity and reverse ICB resistance.

• Publication year

  2025

• Venue

  Advancement of science

• Publication date

  2025-11-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/advs.202506518PMID 41215476PMCID 12849997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From mechanism to therapy: How EIPA modulates dendritic cell-mediated allergic responses via IL-12b and TIM4.

  2025cited by this paper
• Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast Cancer

  2025cited by this paper
• Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma.

  2024cited by this paper
• Palmitoylation of vacuole membrane protein 1 promotes small extracellular vesicle secretion via interaction with ALIX and influences intercellular communication

  2024cited by this paper
• Batf3+ DCs and the 4–1BB/4–1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy

  2024cited by this paper
• Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration

  2024cited by this paper
• Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides

  2023cited by this paper
• Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer

  2023cited by this paper
• Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine

  2023cited by this paper
• Restoring tumor immunogenicity with dendritic cell reprogramming

  2023cited by this paper
• Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape

  2022cited by this paper
• Macrophages induce cardiomyocyte ferroptosis via mitochondrial transfer.

  2022cited by this paper
• Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

  2022cited by this paper
• Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome

  2022cited by this paper
• CDC37L1 acts as a suppressor of migration and proliferation in gastric cancer by down-regulating CDK6

  2021cited by this paper
• A single‐cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast

  2021cited by this paper
• Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.

  2021cited by this paper
• Dendritic cell migration in inflammation and immunity

  2021cited by this paper
• Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity

  2021cited by this paper
• Turning tumors from cold to inflamed to improve immunotherapy response.

  2021cited by this paper
• Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

  2021cited by this paper
• A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

  2021cited by this paper
• Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity.

  2020cited by this paper
• Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

  2020cited by this paper
• Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis

  2020cited by this paper
• Antigen Cross-Presentation by Macrophages

  2020cited by this paper
• The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens

  2020cited by this paper
• The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

  2020cited by this paper
• PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

  2020cited by this paper
• A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

  2020cited by this paper
• Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

  2020cited by this paper
• Turning up the heat on non-immunoreactive tumours: opportunities for clinical development.

  2020cited by this paper
• The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

  2019cited by this paper
• Regulation of Antigen Export to the Cytosol During Cross-Presentation

  2019cited by this paper
• Tumor mutational load predicts survival after immunotherapy across multiple cancer types

  2019cited by this paper
• β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma.

  2019cited by this paper
• Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells

  2019cited by this paper
• Phagocytosis checkpoints as new targets for cancer immunotherapy

  2019cited by this paper
• Dendritic cells in cancer immunology and immunotherapy

  2019cited by this paper
• Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer

  2019cited by this paper
• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

  2019cited by this paper
• The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin II Encapsulated Into Liposomes

  2018cited by this paper
• Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.

  2018cited by this paper
• NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

  2018cited by this paper
• Activation of human CD141+ and CD1c+ dendritic cells in vivo with combined TLR3 and TLR7/8 ligation

  2018cited by this paper
• Downregulation of Membrane Trafficking Proteins and Lactate Conditioning Determine Loss of Dendritic Cell Function in Lung Cancer.

  2018cited by this paper
• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

  2018cited by this paper
• Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

  2018cited by this paper
• A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

  2018cited by this paper
• Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific

  2018cited by this paper
• Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

  2018cited by this paper
• The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity

  2018cited by this paper
• Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

  2018cited by this paper
• WDFY4 is required for cross-presentation in response to viral and tumor antigens

  2018cited by this paper
• Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

  2018cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017cited by this paper
• Of Human DC Migrants and Residents.

  2017cited by this paper
• Differential requirement of Rab22a for the recruitment of ER-derived proteins to phagosomes and endosomes in dendritic cells

  2017cited by this paper
• Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity

  2017cited by this paper
• Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer

  2017cited by this paper
• Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export

  2017cited by this paper
• Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

  2017cited by this paper
• The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.

  2017cited by this paper
• Cellular uptake of extracellular vesicles is mediated by clathrin‐independent endocytosis and macropinocytosis

  2017cited by this paper
• The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

  2016cited by this paper
• Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

  2016cited by this paper
• The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine

  2016cited by this paper
• Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

  2016cited by this paper
• The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I–peptide complex formation

  2016cited by this paper
• Lipid peroxidation causes endosomal antigen release for cross-presentation

  2016cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Human natural killer cells promote cross‐presentation of tumor cell‐derived antigens by dendritic cells

  2015cited by this paper
• ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.

  2015cited by this paper
• Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets

  2015cited by this paper
• Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth

  2015cited by this paper
• Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Routes and mechanisms of extracellular vesicle uptake

  2014cited by this paper
• IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples

  2014cited by this paper
• Beyond DNA repair, the immunological role of PARP‐1 and its siblings

  2013cited by this paper
• Characterization of resident and migratory dendritic cells in human lymph nodes

  2012cited by this paper
• Quantitative Proteomics Reveals That Only a Subset of the Endoplasmic Reticulum Contributes to the Phagosome*

  2012cited by this paper
• Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

  2012cited by this paper
• Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.

  2012cited by this paper
• Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival

  2012cited by this paper
• Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells

  2011cited by this paper
• Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells.

  2011cited by this paper
• Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells.

  2011cited by this paper
• Origin and development of dendritic cells

  2010cited by this paper
• Cellular Internalization of Exosomes Occurs Through Phagocytosis

  2010cited by this paper
• Liver Cytochrome P450 3A Ubiquitination in Vivo by gp78/Autocrine Motility Factor Receptor and C Terminus of Hsp70-interacting Protein (CHIP) E3 Ubiquitin Ligases

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells.

  2008cited by this paper
• Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

  2008cited by this paper
• Targeting the oncogene and kinome chaperone CDC37

  2008cited by this paper
• Topical TLR9 agonists induce more efficient cross‐presentation of injected protein antigen than parenteral TLR9 agonists do

  2007cited by this paper
• NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells.

  2006cited by this paper
• A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells.

  2006cited by this paper
• Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells.

  2005cited by this paper
• Hsp90 and Cdc37 -- a chaperone cancer conspiracy.

  2005cited by this paper

• Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast Cancer

  2025cites this paper